Trump presidency could prove a salve for pharma merger deals
NEW YORK (Reuters) - Biotechnology companies, whose U.S. shares soared Wednesday after Republican Donald Trump's presidential election, may soon see another benefit: an uptick in biotech M&A.
No comments:
Post a Comment